INmune Bio, Inc. / Fundamentals
Income statement
- Net revenue
€42.90K - Cost of goods sold
€0.00 - Gross profit
€42.90K - SG&A expenses
€7.64M - R&D expenses
€26.48M - EBITDA
-€48.24M - D&A
€8.12M - EBIT
-€48.24M - Interest expenses
€0.00 - EBT
-€47.63M - Tax expenses
€0.00 - Net income
-€47.63M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€18.15M - Changes in working capital
-€4.93M - Operating cash flow
-€27.63M - Capex
€605.75K - Other investing cash flow
€0.00 - Net investing cash flow
-€605.75K - Total cash dividends paid
€0.00 - Issuance of common stock
€29.66M - Debt repayment
-€4.29M - Other financing cash flow
€4.53M - Net financing cash flow
€30.25M - Foreign exchange effects
-€12.87K - Net change in cash
€1.98M - Cash at end of period
€28.63M - Free cash flow
-€27.02M
Balance sheet
- Cash and cash equivalents
€28.63M - Cash and short-term investments
€28.63M - Total receivables
€1.85M - Inventory
€0.00 - Other current assets
€433.29K - Total current assets
€30.92M - Property, plant & equipment
€320.89K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€1.09M - Total non-current assets
€1.42M - Total assets
€32.33M - Accounts payable
€6.74M - Short-term debt
€377.52K - Other current liabilities
-€188.76K - Total current liabilities
€7.37M - Long-term debt
€198.20K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€198.20K - Total liabilities
€7.56M - Common stock
€23.17K - Retained earnings
-€169.28M - Other equity
-€654.65K - Total equity
€24.77M - Total liabilities and shareholders' equity
€32.33M
Company information
- Market capitalization
€105.52M - Employees
13 - Enterprise Value
€168.78M
Company ratios
- Gross margin
-
100.0% Much worse than peer group: 6,663.0% - EBITDA margin
-
-112,458.0% Much worse than peer group: 408,062.3% - EBIT margin
-
-112,458.0% Much worse than peer group: 417,335.2% - EBT margin
-
-111,016.0% Much worse than peer group: 406,807.5% - Net margin
-
-111,016.0% Much worse than peer group: 395,174.3% - ROE
-
-192.3% Much worse than peer group: -37.2% - ROA
-
-147.3% Much better than peer group: -15,469.7% - Asset turnover
-
0.1% Much worse than peer group: 68.1% - FCF margin
-
-65,808.0% Much worse than peer group: 543,960.0% - FCF yield
-26.8% - Efficiency ratio
112,558.0% - Net sales per employee
-
€3.30K - Net income per employee
-
-€3.66M